GIMBHI’s daily mental health update — 05/06/26

🧩 Value-based care won’t fully solve autism therapy’s structural payment problems, executives warn (Chris Larson, Behavioral Health Business) — 05/06/26
TL;DR: At VALUE 2026, Kyo Autism Therapy and Behaven Kids leaders argued value-based care can improve quality only with well-designed metrics, citing Kyo’s Magellan model where 80% of patients progressed despite reduced hours.

💊 Psychiatrist urges nuanced view of HHS deprescribing push, warns against antipsychiatry oversimplification (Leah Kuntz & Joseph F. Goldberg, MD, Psychiatric Times) — 05/06/26
TL;DR: Following HHS’s MAHA initiative targeting psychiatric overprescribing, ASCP’s Dr. Goldberg argues deprescribing means replacing ineffective medications with evidence-based alternatives like therapy or neuromodulation—not abandoning treatment for depression, which affects millions and causes 50,000 US suicides yearly.

⚓ Talkspace expands U.S. Navy partnership to 13 installations, reaching 40,000+ Sailors and families (Business Wire) — 05/06/26
TL;DR: Talkspace (NASDAQ: TALK) extended its Navy partnership across 13 installations, providing 40,000+ Sailors and families with self-paced behavioral health support via Talkspace Go plus therapy through TRICARE benefits.

🏥 Hochul awards $13.7M to expand and upgrade inpatient psychiatric units across New York (Travel And Tour World) — 04/30/26
TL;DR: NY’s Office of Mental Health is funding 13 projects across nine providers — three to add inpatient bed capacity and 10 to upgrade patient environments — building on Hochul’s broader push that has already added 1,000 psychiatric beds statewide.

🚶 Mount Boucherie Senior Secondary’s fourth annual mental health walk raises $20K for CMHA Kelowna (Brayden Ursel, Today in BC) — 05/05/26
TL;DR: Roughly 2,300 students from MBSS and neighbouring schools joined former NHL player Jordin Tootoo for the fourth annual Walk for Mental Health, raising about $20,000 for CMHA Kelowna’s Foundry youth program in West Kelowna.

🍄 MSICS Pharma raises $3.6M for psilocybin-based mental health treatments targeting PTSD, depression, OCD (Meir Orbach, CTech) — 05/03/26
TL;DR: Israel’s MSICS Pharma — the only EU/Israel firm with a Health Ministry GMP license to manufacture psilocybin — raised $3.6M from Fusion VC, GlenRock and others to scale Phase II trials for treatment-resistant depression, OCD, and an upcoming multi-hospital PTSD study.